Prolactinoma, the most common functional pituitary neuroendocrine tumor, belongs to Pit-1 lineage of pituitary neuroendocrine tumors. The treatment methods include surgery, medication, and radiation therapy, with drug therapy centered around dopamine receptor agonists. Cabergoline, a selective D2 receptor agonist with high receptor affinity and long-acting properties, is recommended as a first-line treatment in international guidelines for prolactinoma management.Based on the 2014 edition, the "Consensus on the diagnosis and treatment of pituitary prolactinoma (2025 edition)" has made important updates to the treatment recommendations for cabergoline, mainly including: For patients with bromocriptine resistance, if cabergoline is available, switching to cabergoline is recommended as the first choice; For patients receiving long-term, high-dose cabergoline treatment, regular echocardiogram monitoring is recommended to assess the condition of heart valves. Meanwhile, it also provides more detailed elaborations on cabergoline's efficacy, adverse reactions (such as heart valve disease, impulse control disorders, etc.), and its application in drug-resistant prolactinomas. However, since cabergoline has not yet been marketed in Chinese mainland, the practical clinical experience with this drug in the domestic setting remains relatively limited, and there is a lack of systematic summary of local data. Endocrinologists need to pay special attention to the selection of its indications, efficacy evaluation, and safety monitoring during long-term medication.
垂体泌乳素腺瘤属于Pit-1谱系的垂体神经内分泌肿瘤，为最常见的功能性腺瘤。其治疗手段包括手术、药物、放疗，其中药物治疗以多巴胺受体激动剂为核心。卡麦角林作为一种高选择性D2受体激动剂，凭借其强受体亲和力与长效作用机制，已被国际诊疗指南广泛推荐为一线治疗药物。《垂体泌乳素腺瘤诊治共识（2025版）》在2014版基础上对卡麦角林的治疗推荐进行了重要更新，主要包括：对于溴隐亭耐药患者，若能够获得卡麦角林，推荐首选换药；对于接受长期大剂量卡麦角林治疗的患者，推荐定期监测超声心动图，了解心脏瓣膜情况；同时还就其疗效、不良反应（如心脏瓣膜病变、冲动控制障碍等）及在耐药泌乳素腺瘤中的应用作出了更详细的阐述；然而，由于卡麦角林目前尚未在我国上市，该药物在国内临床的实际使用经验仍较为有限，缺乏系统性的本土数据总结。内分泌医师需特别关注其适应证选择、疗效评估及长期用药安全性监测。.